Literature DB >> 30302230

A discussion of blood cancers and the MPN landmark survey.

Claire Harrison1.   

Abstract

Professor Claire Harrison speaks to Roshaine Wijayatunga, managing commissioning editor: Professor Claire Harrison became a consultant at Guy's and St Thomas' hospital in 2001. She is also deputy clinical director of cancer and hematology. She has influenced major advances in her field, including the description of key mutations and designing/leading global clinical trials, for example, the first JAK inhibitor trial in Europe. She is the chief investigator for several other international and national clinical trials. She has strong international collaborations and authors many papers in peer-reviewed journals such as the New England Journal of Medicine and Blood. She has worked with enthusiastic patients to create a patient charity, MPN Voice. She is an internationally regarded expert in her field as a patient advocate.

Entities:  

Keywords:  BCR-ABL; MPNs; hematology; myeloproliferative neoplasms

Year:  2017        PMID: 30302230      PMCID: PMC6171980          DOI: 10.2217/ijh-2017-0024

Source DB:  PubMed          Journal:  Int J Hematol Oncol        ISSN: 2045-1393


  2 in total

1.  Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.

Authors:  Ruben Mesa; Carole B Miller; Maureen Thyne; James Mangan; Sara Goldberger; Salman Fazal; Xiaomei Ma; Wendy Wilson; Dilan C Paranagama; David G Dubinski; John Boyle; John O Mascarenhas
Journal:  BMC Cancer       Date:  2016-02-27       Impact factor: 4.430

2.  The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.

Authors:  Claire N Harrison; Steffen Koschmieder; Lynda Foltz; Paola Guglielmelli; Tina Flindt; Michael Koehler; Jonathan Mathias; Norio Komatsu; Robert N Boothroyd; Amber Spierer; Julian Perez Ronco; Gavin Taylor-Stokes; John Waller; Ruben A Mesa
Journal:  Ann Hematol       Date:  2017-08-05       Impact factor: 3.673

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.